Thananchanoke Rattanathada
Thammasat University, Thailand
Title: Development of oral pharmaceutical formulation of standardized crude ethanolic extract of Atractylodes lancea (Thunb.) DC.
Biography
Biography: Thananchanoke Rattanathada
Abstract
Cholangiocarcinoma (CCA), the adenocarcinoma of the biliary duct, is commonly reported in Asia with the highest incidence in northeastern Thailand. Chemotherapy of this type of cancer is limited by the lack of effective chemotherapeutic drugs. A series of previous in vitro and in vivo studies supports further research and development of Atractylodes lancea (Thumb) DC. (AL) as a potential candidate for the treatment of CCA as a crude ethanolic extract. The dried rhizome of AL in the family Compositae, has been used in Chinese (“Cang Zhu”), Japanese (“So-jutsu”), and Thai (“Khod-Kha-Mao”) traditional medicines for diverse pharmacological qualities including anticancer, antimicrobial activities, anti-inflammatory, and activities on gastrointestinal, central nervous, and cardiovascular systems. These traditional uses are explained by its properties in eliminating dampness, strengthening the spleen, expelling wind-cold from the superficial parts of the body, and relieving the common cold. Objective: The purpose of the research was to develop oral pharmaceutical formulation (capsule) of the standardized AL crude ethanolic extract for further clinical development in patients with CCA. Methods: Major steps included macroscopic and microscopic authentication of the AL rhizomes, preparation of standardized AL extract, preparation of oral pharmaceutical formulation (capsule) of the standardized AL extract, quantitative and qualitative analysis of the marker compound (atractylodin) in the formulated AL extract, evaluation of physicochemical and pharmaceutical properties of the formulated AL extract/capsule, and cytotoxicity evaluation of the formulated AL extract. Results: Results of all evaluations confirm satisfactory pharmaceutical properties of oral (capsule) formulation of the standardized AL extract. Conclusion: This study shows that the formulated AL extract passed the criteria for further clinical evaluation.